KBC Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$92K Hold
1,774
﹤0.01% 1371
2025
Q4
$88K Hold
1,774
﹤0.01% 1376
2025
Q3
$85K Hold
1,774
﹤0.01% 1363
2025
Q2
$56K Sell
1,774
-905
-34% -$29K ﹤0.01% 1557
2025
Q1
$88K Hold
2,679
﹤0.01% 1556
2024
Q4
$97K Buy
2,679
+929
+53% +$32.7K ﹤0.01% 1582
2024
Q3
$55K Sell
1,750
-25
-1% -$780 ﹤0.01% 1672
2024
Q2
$47K Hold
1,775
﹤0.01% 1657
2024
Q1
$61K Hold
1,775
﹤0.01% 1433
2023
Q4
$51K Hold
1,775
﹤0.01% 1514
2023
Q3
$49K Sell
1,775
-2,373
-57% -$72.2K ﹤0.01% 1466
2023
Q2
$125K Sell
4,148
-446
-10% -$15.6K ﹤0.01% 1104
2023
Q1
$166K Hold
4,594
﹤0.01% 1039
2022
Q4
$164K Hold
4,594
﹤0.01% 1035
2022
Q3
$156K Hold
4,594
﹤0.01% 1038
2022
Q2
$133K Buy
+4,594
New +$132K ﹤0.01% 1118
2020
Q1
Sell
-13,592
Closed -$322K 1433
2019
Q4
$322K Hold
13,592
﹤0.01% 1214
2019
Q3
$374K Sell
13,592
-8,917
-40% -$264K ﹤0.01% 1153
2019
Q2
$745K Hold
22,509
0.01% 947
2019
Q1
$789K Buy
+22,509
New +$838K 0.01% 932
2018
Q4
Sell
-9,306
Closed -$469K 1372
2018
Q3
$469K Hold
9,306
﹤0.01% 1116
2018
Q2
$557K Sell
9,306
-19,052
-67% -$987K ﹤0.01% 960
2018
Q1
$1.3M Hold
28,358
0.01% 695
2017
Q4
$1.13M Hold
28,358
0.01% 762
2017
Q3
$1.13M Hold
28,358
0.01% 774
2017
Q2
$1.22M Buy
+28,358
New +$1.01M 0.01% 719

Other funds holding SUPN

KBC Group's SUPN Position: Q1 2026 in Review

KBC Group held its Supernus Pharmaceuticals (SUPN) position steady in Q1 2026 at 1,774 shares worth $92K. The position accounts for ﹤0.01% of the portfolio, ranked #1371.

KBC Group first reported a position in SUPN in Q2 2017 and has held it in 26 quarters since. The position peaked at $1.3M in Q1 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • KBC Group held 1,774 shares of Supernus Pharmaceuticals worth $92K as of Q1 2026.
  • KBC Group left its Supernus Pharmaceuticals share count unchanged in Q1 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1371 holding.
  • KBC Group first reported a position in Supernus Pharmaceuticals in Q2 2017 and has held it in 26 quarters since.
  • KBC Group's Supernus Pharmaceuticals position peaked at $1.3M in Q1 2018.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.